From the Editor

Sep 01, 2006
Pharmaceutical Executive
The world according to New Hampshire: Doctors prescribe expensive drugs because pharma reps sell them. Interfere with the selling, and you'll cut down on the prescribing. It's a plan. But for what?
Aug 01, 2006
Pharmaceutical Executive
The road forward for both public health and the industry is going to require more trust and intimacy, not less, between patients, physicians, FDA, and pharma. Patients need to see a fully functioning set of checks and balances—not what they're seeing today.
Jul 01, 2006
Pharmaceutical Executive
I needed to eat. I even wanted to eat. Instead, I sat in front of my hospital lunch tray, unable to face up to a carton of red Jell-O. When you think of it, that's a situation most of us face (minus the Jell-O) every day in business.
Jun 01, 2006
Pharmaceutical Executive
At the rate science is progressing, there may be more new knowledge in the next 25 years than in the past 100. That's great news, but not if you are planning to run your business as you run it today.
May 01, 2006
Pharmaceutical Executive
Where is pharma going? Toward more science, and more political pressure on science. Toward greater patient responsibility—and more regulation-by-lawsuit. And forward. Let's not forget about forward.
Apr 01, 2006
Pharmaceutical Executive
Safety advocates want to make it tougher for new drugs to win FDA approval. Consumer advocates want to make it legal to import drugs from abroad. Put those ideas together, and what have you got?
Mar 01, 2006
Pharmaceutical Executive
The newspapers seem shocked to learn that scientific journals occasionally publish things that aren't true. Where have they been?
Feb 01, 2006
Pharmaceutical Executive
Is the public ready for an exciting thriller about terrorism, drug counterfeiting, valiant FDA agents, and glamorous women who invite pharma CEOs to come up and look at their drug patents? Sure. Maybe someone should write one.
Jan 01, 2006
Pharmaceutical Executive
Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.
Dec 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The public is focused on drug safety, but the real issue isn't approval standards. It's the way drugs expand to unapproved new indications. Are you listening, Acomplia?
native1_300x100
lorem ipsum